Lonza Group Ag (OTCMKTS:LZAGY) Short Interest Up 281.6% in June

Lonza Group Ag (OTCMKTS:LZAGYGet Free Report) was the recipient of a large increase in short interest in June. As of June 30th, there was short interest totaling 31,620 shares, an increase of 281.6% from the June 15th total of 8,286 shares. Based on an average trading volume of 93,974 shares, the short-interest ratio is currently 0.3 days. Currently, 0.0% of the company’s shares are sold short.

Lonza Group Price Performance

Lonza Group stock traded up $0.40 during trading on Friday, hitting $72.63. 29,934 shares of the company were exchanged, compared to its average volume of 44,285. The business’s 50 day moving average is $63.99 and its 200 day moving average is $65.47. Lonza Group has a 52 week low of $58.53 and a 52 week high of $73.85. The company has a current ratio of 2.24, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42.

Analyst Ratings Changes

Separately, Zacks Research upgraded shares of Lonza Group from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 8th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Lonza Group presently has a consensus rating of “Moderate Buy”.

View Our Latest Stock Report on Lonza Group

Lonza Group Company Profile

(Get Free Report)

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.

See Also

Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.